Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Safety and Efficacy of Enavogliflozin (DWP16001) in T2DM Patients
NCT06141980Phase 3Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of enavogliflozin in type 2 diabetes mellitus (T2DM), sponsored by Daewoong Pharmaceutical. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06141980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141980.